Sugi Predict

Sugi Predict / Compounds / SCHEMBL3311541

SCHEMBL3311541

SCHEMBL3311541

O=C(O)N[C@@H](CO)c1ccccc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RIPK1 Q13546 1/20 0.60
▸ EPHX2 P34913 2/20 0.55
▸ ROCK2 O75116 4/20 0.54
▸ ROCK1 Q13464 4/20 0.54
▸ MAPK13 O15264 1/20 0.54
▸ RPS6KA5 O75582 1/20 0.54
▸ MAP4K4 O95819 1/20 0.54
▸ PAK4 O96013 1/20 0.54
▸ PRKCG P05129 1/20 0.54
▸ CDK1 P06493 1/20 0.54
▸ PRKACA P17612 1/20 0.54
▸ RPS6KB1 P23443 1/20 0.54
▸ CDK2 P24941 1/20 0.54
▸ MAPK1 P28482 1/20 0.54
▸ AKT1 P31749 1/20 0.54
▸ AKT2 P31751 1/20 0.54
▸ CLK2 P49760 1/20 0.54
▸ GSK3A P49840 1/20 0.54
▸ GSK3B P49841 1/20 0.54
▸ IRAK1 P51617 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL117597 1.00 RIPK1 (0.60) RIPK1EPHX2ROCK2ROCK1MAPK13
SCHEMBL668277 1.00 RIPK1 (0.60) RIPK1EPHX2ROCK2ROCK1MAPK13
SCHEMBL6939333 0.88 RIPK1 (0.54) RIPK1EPHX2ROCK2ROCK1MAPK13
SCHEMBL4332848 0.88 RIPK1 (0.60) RIPK1EPHX2ROCK2ROCK1MAPK13
SCHEMBL28136628 0.87 RIPK1 (0.52) RIPK1EPHX2ROCK2ROCK1MAPK13
SCHEMBL4337456 0.86 RIPK1 (0.58) RIPK1EPHX2ROCK2ROCK1MAPK13
SCHEMBL21523031 0.84 GPR88 (0.58) RIPK1GPR88METAP2METAP1
SCHEMBL21331612 0.84 GPR88 (0.58) RIPK1GPR88METAP2METAP1
SCHEMBL21331611 0.84 GPR88 (0.58) RIPK1GPR88METAP2METAP1
SCHEMBL21331610 0.84 GPR88 (0.58) RIPK1GPR88METAP2METAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2007509075-A — — 2007-04-12 — — JP claimed
CN-1898234-A Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORP (US) 2007-01-17 — — CN claimed
EP-1678167-A1 SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES Incyte Corporation (US) 2006-07-12 — — EP claimed
WO-2005037826-A1 SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES INCYTE CORPORATION (US) 2005-04-28 — — WO claimed
US-11958844-B2 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2024-04-16 — — US disclosed
EP-3827004-B1 4-(1,3,4-OXADIAZOLE-2-YL)PYRIDINE-2(1H)-ONE DERIVATIVES AS HISTONE DEACETYLASE 6 (HDAC6) INHIBITORS FOR THE TREATMENT OF E.G. INFECTIONS CHONG KUN DANG PHARMACEUTICAL CORP (KR) 2023-10-11 — — EP disclosed
US-20220242831-A1 IMPROVED PROCESS FOR THE PREPARATION OF ELAGOLIX AND ITS INTERMEDIATES DR. REDDY'S LABORATORIES LIMITED (IN) 2022-08-04 — — US disclosed
US-20210188831-A1 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2021-06-24 — — US disclosed
EP-3827004-A1 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME Chong Kun Dang Pharmaceutical Corp. (KR) 2021-06-02 — — EP disclosed
WO-2020022794-A1 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2020-01-30 — — WO disclosed
US-9447090-B2 Imidazopyridine compounds ASTELLAS PHARMA INC. (JP) 2016-09-20 — — US disclosed
EP-2716642-B1 IMIDAZOPYRIDINE COMPOUND ASTELLAS PHARMA INC (JP) 2016-07-20 — — EP disclosed
US-7652049-B2 1-benzyl-4-[4'-fluoro-5'-isopropyl-2'-methoxy-4-(trifluoromethyl)biphenyl-2-yl]imidazolidin-2-one; cholesteryl ester transfer protein inhibitor; raising HDL-cholesterol, reducing LDL-cholesterol; atherosclerosis; antiinflammatory agent; synergistic mixture with other active ingredients MERCK & CO., INC. (US) 2010-01-26 — — US disclosed
US-20080318947-A1 Inhibitors of Akt Activity HEERDING DIRK A 2008-12-25 — — US disclosed
US-20080119476-A1 Cetp Inhibitors ALI AMJAD 2008-05-22 — — US disclosed
CN-1898234-A Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORP (US) 2007-01-17 — — CN disclosed
US-20060040999-A1 CETP inhibitors MERCK SHARP & DOHME LLC 2006-02-23 — — US disclosed
US-5589476-A TREATMENT OF NAUSEA, VOMITING AND GASTROINTESTINAL DISORDERS SYNTHELABO (FR) 1996-12-31 — — US disclosed
EP-0646583-A1 Derivatives of Imidezol-4-yl piperidine, their preparation and use in therapy SYNTHELABO (FR) 1995-04-05 — — EP disclosed
US-5087726-A Carbamate ACAT inhibitors WARNER-LAMBERT COMPANY (US) 1992-02-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060040999-A1 CETP inhibitors CETP, APOB, MTTP RIPK1 3818/4885EPHX2 908/4885ROCK2 3544/4885
US-20080119476-A1 Cetp Inhibitors CETP, APOB, MTTP RIPK1 3818/4885EPHX2 908/4885ROCK2 3544/4885
US-11958844-B2 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same HDAC6, HDAC1, HDAC3 RIPK1 2705/4885EPHX2 2867/4885ROCK2 3054/4885
US-20210188831-A1 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME HDAC6, HDAC1, HDAC3 RIPK1 2705/4885EPHX2 2867/4885ROCK2 3054/4885
US-20080318947-A1 Inhibitors of Akt Activity PI4KB, PIK3CA, AKT2 RIPK1 326/4885EPHX2 4446/4885ROCK2 499/4885
US-20220242831-A1 IMPROVED PROCESS FOR THE PREPARATION OF ELAGOLIX AND ITS INTERMEDIATES PCSK9, XPO5, HAX1 RIPK1 4119/4885EPHX2 443/4885ROCK2 2016/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.